(
out of
195
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
Hematology/Oncology
1950 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Internal Medicine (Sub: Hematology)
National Board of Medical Examiners
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
Patients consistently describe Dr. Galarza-Fortuna as knowledgeable, thorough, and compassionate. Many note that she explains diagnoses and treatment options clearly, takes time to answer questions, and makes them feel heard and reassured. Several comments highlight her supportive bedside manner during difficult treatments and her ability to make complex medical information easy to understand. Overall feedback emphasizes strong communication, empathy, and clinical competence.
Generated via Patient Reviews
4.9
/5
( out of
195 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Assistant Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Sub: Hematology)
National Board of Medical Examiners
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Education history
| Undergraduate | Major: Psychology; Minor: Health Sciences - Manhattanville University | B.A. |
|---|---|---|
| Professional Medical | Medicine - Universidad Iberoamericana | M.D. |
| Residency | Internal Medicine - Mount Sinai Medical Center | Resident |
| Residency | Internal Medicine - Mount Sinai Medical Center | Academic Chief Resident |
| Fellowship | Hematology & Oncology - University of Utah Spencer Fox Eccles School of Medicine | Fellow |
| Fellowship | Hematology & Oncology - University of Utah Spencer Fox Eccles School of Medicine | Chief Fellow |
Selected Publications
Journal Article
- Rahbari KJ, Galarza Fortuna GM, Dholaria B, Sborov DW, Baljevic (2026). Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma. British journal of haematology,
- Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3),
- Ozay ZI, Jo Y, Galarza Fortuna G, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Anderson E, Jaime-Casas S, Zugman M, Mathew Thomas V, Maughan BL, Agarwal N, Pal SK, Swami (2025). Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US. JAMA network open, 8(3), e251201.
- Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov D (2025). Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. Blood advances, 9(23), 6009-6018.
- Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J, 14(1), 20.
- Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami U (2024). Predictors of response to neoadjuvant therapy in urothelial cancer. Crit Rev Oncol Hematol, 194, 104236.
- Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami (2024). Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer, 130(15), 2621-2628.
- Zanwar S, Galarza Fortuna GM, Sborov D (2024). Risk-adapted treatment in multiple myeloma: Does more make it merrier?. British journal of haematology, 205(3), 767-769.
- Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA network open, 7(7), e2423186.
- Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami (2024). Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. European urology oncology,
- Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA network open, 7(5), e249417.
- Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal (2024). Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. The Prostate, 84(9), 888-892.
- Sborov DW, Fortuna GG, Hayden P (2024). Sequence not salvage. British journal of haematology, 204(5), 1590-1592.
- Dal E, Srivastava A, Chigarira B, Hage Chehade C, Matthew Thomas V, Galarza Fortuna GM, Garg D, Ji R, Gebrael G, Agarwal N, Swami U, Li (2024). Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. Diagnostics (Basel, Switzerland), 14(17),
- Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan B (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Therapeutic advances in urology, 16, 17562872241293779.
- Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami (2024). Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI. JCO precision oncology, 8, e2300574.
- Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N (2023). Advances in the treatment of metastatic prostate cancer. Trends Cancer, 9(10), 840-854.
- Gebrael G, Fortuna GG, Agarwal N (2023). Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma. JAMA Oncol, 9(8), 1033-1035.
- Fortuna GMG, Guerra V, Chaaya G (2021). Acquired factor V inhibitor presenting as life threatening bleeding after initiation of apixaban. Haemophilia, 27(5), e636-e637.
- Dvir K, Galarza-Fortuna GM, Haines JM, Gines P, Ruiz AL, Rodriguez E (2021). Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting. J Immunother Precis Oncol, 4(1), 1-5.
- Fortuna GMG, Rios P, Rivero A, Zuniga G, Dvir K, Pagacz MM, Manzano (2020). Papillary Thyroid Carcinoma With Cystic Changes in a Patient With Prior History of Toxic Nodule. Journal of investigative medicine high impact case reports, 8, 2324709620942672.
Review
- Galarza Fortuna GM, Singh A, Jacobs A, Ugalde (2020). Lung Adenocarcinoma Presenting as Multiple Thromboembolic Events: A Case Report and Review of the Literature. Journal of investigative medicine high impact case reports, 8, 2324709620969482.
- Galarza Fortuna GM, Dvir (2020). Circulating tumor DNA: Where are we now? A mini review of the literature. World journal of clinical oncology, 11(9), 723-731.
Case Report
- Dvir K, Galarza-Fortuna GM, Willet A, Febres-Aldana C, Cortez N, Rapaka S, Coombs A, Goldberg R, Schwartz M, Ben-David (2020). A Rare Case of Light Chain Amyloidosis of the Gastrointestinal Tract. Case reports in surgery, 2020, 1921805.
- Cortez N, Berzosa M, Mahfouz M, Dvir K, Galarza Fortuna GM, Ben-David (2020). Diagnosis and Treatment of Metastatic Disease to the Pancreas. Journal of laparoendoscopic & advanced surgical techniques. Part A, 30(9), 1008-1012.
- Febres-Aldana AJ, Febres-Aldana CA, Dvir K, Galarza-Fortuna G, Schwartz M, Medina AM, Sriganeshan (2020). Reactivation of Epstein-Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment. Case reports in hematology, 2020, 3641813.
- Galarza Fortuna GM, Dvir K, Febres-Aldana C, Schwartz M, Medina A (2019). Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature. Journal of investigative medicine high impact case reports, 7, 2324709619893548.
- Dvir K, Fortuna GMG, Schwartz (2019). Delayed Presentation of Thymoma-Related Aplastic Anemia: An Unusual Presentation of a Rare Complication. Journal of hematology, 8(4), 160-164.
Editorial
- Galarza Fortuna GM, Maughan B (2024). The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the modern era. Translational andrology and urology, 13(5), 915-919.
Letter
- Galarza Fortuna GM, Rahbari KJ, Baljevic M, Sborov D (2026). "Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT": comment from Galarza Fortuna et al. Journal of thrombosis and haemostasis, 24(1), 337-340.
- Galarza Fortuna GM, Swami U, Gupta (2025). Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)". Journal for immunotherapy of cancer, 13(5),
- Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma, 65(9), 1362-1365.
Great doctor I'm glad to have her on my side!
She is the best. She explained a new procedure that may be available to me in the near future. sounds very promising.
Dr. Galarza-Fortuna is a great Dr. to see. upfront, communicates, listen to my needs. Glad I have her.
very nice, very concerned
She's very knowledgeable, slow and explaining everything to you very good doctor
Extremely knowledgeable. Took all the time necessary to explain my disease and answer all my questions.
Gliceida really makes us feel heard and cared for.
Dr. Galarza is always pleasant and thorough in her explanation of test results and next steps.
Great Dr. Explain everything so I could understand
Dr Galarza is a wonderful and caring oncologist. She's been amazing! When I was diagnosed I was very sick and had been hospitalized for over 30 days. She walked into my hospital room with a huge smile and told me. If you hang in there we're going to get you better. That was 7 months ago and now I'm preparing for a stem cell transplant. Wish me luck!
Gliceida Maria Galarza-Fortuna, MD was very understanding, explained to me very clearly was was going on and how she was going to handle it.
Professional courteous
Your can't go wrong having Doctor Galatea-Fortuna as your physician.
She makes complicated medical information easy to understand.
Very friendly and reassuring, seems to know her stuff
She has explained everything thoroughly and made sure that we understood her.
She is very kind and truly wants to do what is best for you. There is a little bit of a communication gap but she welcomes questions for clarification.
Dr Gli is awesome. Blood cancer is so scary and she is there very step of the way with encouragement.
Thank you Dr. Galaraza-Fortuna for your knowledge, compassion, and skill in expressing my condition and willingness to answer my questions. My wife and I are blessed to have you as my doctor!
Dr Gli makes eye contact with you and explains everything. She answers all your questions.
Dr Glee so smart and can still explain things so you understand it. A cancer diagnosis is so scary and I feel Dr Glee has my back. She even stood by my bed and 'distracted' me for a lumbar puncture that I was so stressed and scary. I am so grateful I have Dr Glee and her awesome team. Mary is amazing as well.